Jorge Chaves

3.0k total citations · 1 hit paper
41 papers, 1.2k citations indexed

About

Jorge Chaves is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Jorge Chaves has authored 41 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 9 papers in Pathology and Forensic Medicine. Recurrent topics in Jorge Chaves's work include HER2/EGFR in Cancer Research (9 papers), Colorectal Cancer Treatments and Studies (8 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Jorge Chaves is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Colorectal Cancer Treatments and Studies (8 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Jorge Chaves collaborates with scholars based in United States, Canada and South Korea. Jorge Chaves's co-authors include Erika Hamilton, Todd Gray, James L. Gulley, Michael S. Gordon, Virginia F. Borges, Manish R. Patel, Alison Conlin, Matthew H. Taylor, J. Thaddeus Beck and Anja von Heydebreck and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Jorge Chaves

41 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer

2019 319 citations Michael S. Gordon, Manish R. Patel et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jorge Chaves United States	16	909	365	283	211	211	41	1.2k
Zanete Zvirbule Latvia	17	850 0.9×	506 1.4×	89 0.3×	218 1.0×	69 0.3×	45	1.2k
Catherine A. Shu United States	19	1.0k 1.1×	1.0k 2.8×	161 0.6×	265 1.3×	75 0.4×	64	1.5k
Georgy M. Manikhas Russia	11	1.4k 1.6×	1.1k 3.0×	190 0.7×	608 2.9×	81 0.4×	35	2.0k
Stefanie Srock Germany	12	787 0.9×	302 0.8×	105 0.4×	132 0.6×	65 0.3×	21	1.1k
Sara Cresta Italy	20	597 0.7×	461 1.3×	142 0.5×	422 2.0×	37 0.2×	55	1.3k
Elizabeth Crowley United States	16	473 0.5×	242 0.7×	172 0.6×	255 1.2×	25 0.1×	39	1.0k
Patrícia Castro Portugal	20	666 0.7×	117 0.3×	153 0.5×	673 3.2×	107 0.5×	28	1.9k
Christine Böger Germany	16	708 0.8×	479 1.3×	221 0.8×	232 1.1×	28 0.1×	23	1.2k
Analía Azaro Spain	18	557 0.6×	295 0.8×	152 0.5×	569 2.7×	25 0.1×	56	1.1k
Katrin E. Rhodes United States	13	560 0.6×	314 0.9×	151 0.5×	575 2.7×	41 0.2×	21	1.3k

Countries citing papers authored by Jorge Chaves

Since Specialization

Citations

This map shows the geographic impact of Jorge Chaves's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jorge Chaves with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jorge Chaves more than expected).

Fields of papers citing papers by Jorge Chaves

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jorge Chaves. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jorge Chaves. The network helps show where Jorge Chaves may publish in the future.

Co-authorship network of co-authors of Jorge Chaves

This figure shows the co-authorship network connecting the top 25 collaborators of Jorge Chaves. A scholar is included among the top collaborators of Jorge Chaves based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jorge Chaves. Jorge Chaves is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gouda, Mohamed A., Martin H. Voss, Hussein A. Tawbi, et al.. (2025). A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer. ESMO Open. 10(5). 104536–104536. 17 indexed citations

Meric‐Bernstam, Funda, Sun Young Rha, Erika Hamilton, et al.. (2025). Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial. Nature Communications. 16(1). 4293–4293. 5 indexed citations

Enzler, Thomas, Anna Nguyen, Jamal Misleh, et al.. (2024). A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma. European Journal of Cancer. 201. 113950–113950. 2 indexed citations

Kim, Richard D., Mustapha Tehfé, Petr Kavan, et al.. (2024). Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D. Clinical Colorectal Cancer. 23(2). 118–127.e6. 8 indexed citations

Chen, Eric X., Petr Kavan, Mustapha Tehfé, et al.. (2024). Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E. Clinical Colorectal Cancer. 23(2). 183–193. 2 indexed citations

Furman, Richard R., William G. Wierda, Anna Schuh, et al.. (2022). Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with >4 Years of Follow-up. Blood. 140(Supplement 1). 9873–9875. 2 indexed citations

Hurvitz, Sara A., Jorge Chaves, Adam Brufsky, et al.. (2022). Abstract OT1-14-01: Zanidatamab in combination with ALX148 in advanced human epidermal growth factor receptor 2 (HER2)-expressing cancers, including breast cancer: A phase 1b/2, multicenter, open-label, dose-finding and cohort-expansion study (ZWI-ZW25-204). Cancer Research. 82(4_Supplement). OT1–14. 3 indexed citations

Meric‐Bernstam, Funda, Diana L. Hanna, Anthony B. El-Khoueiry, et al.. (2021). Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study.. Journal of Clinical Oncology. 39(3_suppl). 299–299. 51 indexed citations

Chung, Ki Y., Haeseong Park, Deborah B. Doroshow, et al.. (2021). Phase I study of BJ-001, a tumor-targeting interleukin-15 fusion protein, in patients with solid tumor.. Journal of Clinical Oncology. 39(15_suppl). e14545–e14545. 4 indexed citations

10.

Chaves, Jorge, Petr Kavan, Marwan Fakih, et al.. (2020). 493P Pembrolizumab (pembro) plus mFOLFOX7 or FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC): Updated results from KEYNOTE-651 cohorts B and D. Annals of Oncology. 31. S450–S450. 4 indexed citations

11.

Vaishampayan, Ulka N., Patrick Schöffski, Alain Ravaud, et al.. (2019). Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial. Journal for ImmunoTherapy of Cancer. 7(1). 275–275. 49 indexed citations

12.

Murthy, Rashmi K., Virginia F. Borges, Alison Conlin, et al.. (2018). Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. The Lancet Oncology. 19(7). 880–888. 129 indexed citations

13.

Shah, Manish A., Alexander Starodub, Sunil Sharma, et al.. (2018). Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study. Clinical Cancer Research. 24(16). 3829–3837. 78 indexed citations

14.

Ng, Kimmie, Andrew Hendifar, Alexander Starodub, et al.. (2018). Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. Investigational New Drugs. 37(1). 159–165. 32 indexed citations

15.

Vaena, Daniel A., Jorge Chaves, Nicholas J. Vogelzang, et al.. (2018). PROPEL: A phase 1/2 trial of NKTR-214 (CD122-biased agonist) combined with anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 36(15_suppl). TPS3115–TPS3115. 3 indexed citations

16.

Flowers, Christopher R., Carlos Panizo, Iris Isufi, et al.. (2018). Long Term Follow-up of a Phase 2 Study Examining Intratumoral G100 Alone and in Combination with Pembrolizumab in Patients with Follicular Lymphoma. Blood. 132(Supplement 1). 2892–2892. 6 indexed citations

17.

Poondru, Srinivasu, Jorge Chaves, Geoffrey J. Yuen, et al.. (2016). Mass balance, pharmacokinetics, and metabolism of linsitinib in cancer patients. Cancer Chemotherapy and Pharmacology. 77(4). 829–837. 7 indexed citations

18.

Cleary, James M., David A. Reardon, Nilofer S. Azad, et al.. (2015). A phase 1 study of ABT-806 in subjects with advanced solid tumors. Investigational New Drugs. 33(3). 671–678. 28 indexed citations

19.

Borges, Virginia F., Erika Hamilton, Denise A. Yardley, et al.. (2015). Abstract P4-15-08: A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with ado-trastuzumab emtansine (T-DM1), in HER2+ metastatic breast cancer (MBC). Cancer Research. 75(9_Supplement). P4–15. 1 indexed citations

20.

Chaves, Jorge & Muhammad Wasif Saif. (2010). IGF system in cancer. Anti-Cancer Drugs. 22(3). 206–212. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact